Yet GSK is clearly healing from its multiple comorbidities — the worst of which was the (now largely resolved) legal overhang related to heartburn medicine Zantac. Chief executive Emma Walmsley also ...

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted fourth-quarter profit ahead of analyst expectations.

Vivian Wan / Bloomberg via Getty Images GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the ...